Market Tracker

11/17 5:15pm ET

SPDR® S&P Biotech ETF (XBI)

81.43
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
58.66
Today|||52-Week Range
88.98
+37.57%
Year-to-Date

Investment Objective

The investment seeks to provide investment results that- before fees and expenses- correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index")- the fund employs a sampling strategy. It generally invests substantially all- but at least 80%- of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

No recent news for SPDR® S&P Biotech ETF.

Performance

1 month-6.04% 3 years+13.72%
3 months+8.77% 5 years+24.43%
1 year+22.76% Since inception+14.91%
Data through 11/18/2017

Quote Details

Previous close$81.43
Open day’s range80.67 – 81.69
Net asset value (NAV)81.52 (11/17/2017)
Daily volume3,457,443
Average volume (3 months)3,685,908
Data as of 8:00pm ET, 11/17/2017

Peer Comparisonvs. Health ETFs

 XBICategory
Performance 5-yr return+24.43%+16.79%
Expense Gross exp ratio0.35%1.33%
Risk 5 year sharpe ratio0.881.11
Net assets$4.3B$3.1B
Average market cap$4.5B$27.3B
Average P/E--22.4
Dividend / Share--0.28%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
FHLC Fidelity® MSCI Health Care Index ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ALNY Alnylam Pharmaceuticals Inc3.18%
EXAS Exact Sciences Corp2.49%
PBYI Puma Biotechnology Inc2.35%
SGEN Seattle Genetics Inc2.23%
SRPT Sarepta Therapeutics Inc2.21%
AVXS AveXis Inc2.17%
CLVS Clovis Oncology Inc2.16%
BLUE bluebird bio Inc2.15%
NBIX Neurocrine Biosciences Inc2.07%
JUNO Juno Therapeutics Inc2.07%